"Market opportunity for Ulcerative colitis will be huge in the coming years"
Bodes well for Brilacidin-IBD as a novel non-biologic treatment. Looking forward to today's/tomorrow's PR... see how the trial ended up.
"Pfizer has a huge chance to expand XELJANZ to the Ulcerative Colitis market, which is expected to reach $6.798 billion by 2021."
--
Pfizer's positive results in three phase 3 trials should be more than enough to warrant FDA approval. The added market opportunity for XELJANZ in Ulcerative Colitis should give it a boost in revenue in the coming years. Competition is fierce in the space, but the ability for XELJANZ to be given orally instead of as an injection should be a huge advantage over HUMIRA.
Market Data 
Markets 
AI
